{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:11:36Z","timestamp":1761052296446,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.bcmd.2017.01.007","type":"journal-article","created":{"date-parts":[[2017,1,16]],"date-time":"2017-01-16T12:04:05Z","timestamp":1484568245000},"page":"180-184","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Patients with Gaucher type 1: Switching from imiglucerase to miglustat therapy"],"prefix":"10.1016","volume":"68","author":[{"given":"Ebru","family":"Canda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melis","family":"Kose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehtap","family":"Kagnici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sema Kalkan","family":"Ucar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eser Y.","family":"Sozmen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmut","family":"Coker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2017.01.007_bb0005","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0006-291X(65)90743-6","article-title":"Metabolism of glucocerebrosides. II. Evidence of enzymatic deficiency in Gaucher's disease","volume":"18","author":"Brady","year":"1996","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bcmd.2017.01.007_bb0010","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0950-3536(97)80033-9","article-title":"Gaucher's disease: clinical features and natural history","volume":"10","author":"Cox","year":"1997","journal-title":"Baillieres Clin. Haematol."},{"key":"10.1016\/j.bcmd.2017.01.007_bb0015","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1001\/archinte.160.18.2835","article-title":"The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease","volume":"160","author":"Charrow","year":"2000","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.bcmd.2017.01.007_bb0020","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1001\/archinte.158.16.1754","article-title":"Gaucher disease: recommendations on diagnosis, evaluation, and monitoring","volume":"158","author":"Charrow","year":"1998","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.bcmd.2017.01.007_bb0025","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1086\/302925","article-title":"Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease","volume":"66","author":"Koprivica","year":"2000","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bcmd.2017.01.007_bb0030","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/ajh.20908","article-title":"Consequences of diagnostic delays in type 1 Gaucher disease: the need for greater awareness among hematologists-oncologists and an opportunity for early diagnosis and intervention","volume":"82","author":"Mistry","year":"2007","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2017.01.007_bb0035","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00223-008-9143-4","article-title":"Changes of bone metabolism in seven patients with Gaucher disease treated consecutively with imiglucerase and miglustat","volume":"83","author":"Mikosch","year":"2008","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bcmd.2017.01.007_bb0040","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2141.2009.07872.x","article-title":"Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis","volume":"147","author":"Mistry","year":"2009","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2017.01.007_bb0045","doi-asserted-by":"crossref","first-page":"33","DOI":"10.7326\/0003-4819-122-1-199501010-00005","article-title":"Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources","volume":"122","author":"Grabowski","year":"1995","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.bcmd.2017.01.007_bb0050","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/bjh.12804","article-title":"Gaucher disease: haematological presentations and complications","volume":"165","author":"Thomas","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2017.01.007_bb0055","first-page":"407","article-title":"Review of the safety and efficacy of imiglucerase treatment of Gaucher disease","volume":"3","author":"Elstein","year":"2009","journal-title":"Biologicals"},{"key":"10.1016\/j.bcmd.2017.01.007_bb0060","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1542\/peds.2007-2144","article-title":"Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1","volume":"122","author":"Andersson","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.bcmd.2017.01.007_bb0065","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0140-6736(00)02161-9","article-title":"Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis","volume":"355","author":"Cox","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.bcmd.2017.01.007_bb0070","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1023\/B:BOLI.0000045756.54006.17","article-title":"Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease","volume":"27","author":"Elstein","year":"2004","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.bcmd.2017.01.007_bb0075","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/j.clinthera.2007.08.006","article-title":"Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies","volume":"29","author":"Pastores","year":"2007","journal-title":"Clin. Ther."},{"key":"10.1016\/j.bcmd.2017.01.007_bb0080","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0005-2760(95)00217-0","article-title":"Induction of glucosylceramide synthase by synthase inhibitors and ceramide","volume":"1299","author":"Abe","year":"1996","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bcmd.2017.01.007_bb0085","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s10545-012-9528-4","article-title":"Long-term clinical outcomes in type 1 Gaucher disease following 10years of imiglucerase treatment","volume":"36","author":"Weinreb","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.bcmd.2017.01.007_bb0090","article-title":"Enzyme replacement and substrate reduction therapy for Gaucher disease","volume":"3","author":"Shemesh","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.bcmd.2017.01.007_bb0095","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1750-1172-7-102","article-title":"Evaluation of miglustat as maintenance therapy after enzyme therapy in adults with stable type 1 Gaucher disease: a prospective, open-label non-inferiority study","volume":"7","author":"Cox","year":"2012","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.bcmd.2017.01.007_bb0100","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s00247-008-0811-3","article-title":"Splenic nodules in paediatric gaucher disease treated by enzyme replacement therapy","volume":"38","author":"Chippington","year":"2008","journal-title":"Pediatr. Radiol."},{"key":"10.1016\/j.bcmd.2017.01.007_bb0105","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1182\/blood-2007-02-075960","article-title":"Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement","volume":"110","author":"Elstein","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2017.01.007_bb0110","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/ana.21491","article-title":"Randomized, controlled trial of miglustat in Gaucher's disease type 3","volume":"64","author":"Schiffmann","year":"2008","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bcmd.2017.01.007_bb0115","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s10545-014-9725-4","article-title":"Long term differential consequences of miglustat therapy on intestinal disaccharidases","volume":"37","author":"Amiri","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.bcmd.2017.01.007_bb0120","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1023\/A:1025902113005","article-title":"The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement","volume":"26","author":"Cox","year":"2003","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.bcmd.2017.01.007_bb0125","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s10545-011-9368-7","article-title":"Gastrointestinal disturbances and their management in miglustat-treated patients","volume":"34","author":"Belmatoug","year":"2011","journal-title":"J. Inherit. Metab. Dis."}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979616303345?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979616303345?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:33:08Z","timestamp":1761049988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979616303345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":25,"alternative-id":["S1079979616303345"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2017.01.007","relation":{},"ISSN":["1079-9796"],"issn-type":[{"type":"print","value":"1079-9796"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patients with Gaucher type 1: Switching from imiglucerase to miglustat therapy","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2017.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}